Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-centre, Randomised, Open Label, Phase IIb Study to Compare the Efficacy, Safety and Pharmacokinetics (PK) of an Optimised Dosing to a Standard Dosing Regimen of Vancomycin in Neonates and Infants Aged ≤ 90 Days With Late Onset Bacterial Sepsis Known or Suspected to be Caused by Gram-positive Microorganisms

NCT02790996 is registered in ClinicalTrials.gov with PENTA Foundation as lead sponsor.

NCT NCT02790996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02790996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-centre, Randomised, Open Label, Phase IIb Study to Compare the Efficacy, Safety and Pharmacokinetics (PK) of an Optimised Dosing to a Standard Dosing Regimen of Vancomycin in Neonates and Infants Aged ≤ 90 Days With Late Onset Bacterial Sepsis Known or Suspected to be Caused by Gram-positive Microorganisms
Lead sponsor
PENTA Foundation
Phase
Phase 2
Overall status
Terminated
Start date
February 27, 2017
Completion date
April 1, 2020
Enrollment
242 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

late onset neonatal sepsis